26 results on '"Hoellriegl, Werner"'
Search Results
2. Development of an In Vitro Biopotency Assay for an AAV8 Hemophilia B Gene Therapy Vector Suitable for Clinical Product Release
3. Pharmacokinetics, disease-modifying activity, and safety of an experimental therapeutic targeting an immunological isoform of macrophage migration inhibitory factor, in rat glomerulonephritis
4. Treatment with recombinant ADAMTS13, alleviates hypoxia/reoxygenation-induced pathologies in a mouse model of human sickle cell disease
5. A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13
6. Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease
7. Preclinical safety and efficacy of a new recombinant FIX drug product for treatment of hemophilia B
8. AAV8-Specific Immune Adsorption Column: A Treatment Option for Patients with Pre-Existing Anti-AAV8 Neutralizing Antibodies
9. The Factor VIII Variant X5 Enhances Hemophilia a Gene Therapy Efficiency By Its Improved Secretion
10. Detection of Biologically Relevant Low-Titer Neutralizing Antibodies Against Adeno-Associated Virus Require Sensitive In Vitro Assays
11. Evaluation of the Human Factor IX Gene Therapy Vector TAK-748 in Hemophilia: Results from Non-Clinical Studies in Factor IX Knockout Mice and Rhesus Monkeys
12. Nonclinical Safety of SHP 826 (BAX 826), a Next Generation Extended Half-Life Recombinant Factor VIII Product
13. Nonclinical Assessment of Bax 604 (FEIBA STAR) - Reduced Volume Reconstitution & Higher Infusion Rate
14. Pharmacokinetics of BAX 826, a Polysialylated Full-Length rFVIII, in Hemophilia a Mice, Rats, and Cynomolgus Monkeys
15. Lethality of Mouse Tissue Factor Pathway Inhibitor Gene Disruption Is Rescued By Transgenic Human Tissue Factor Pathway Inhibitor Knock in
16. Development of BAX 826, a Polysialylated Full-Length rFVIII with Significantly Improved PK Properties
17. Influence of Obesity on Factor IX Expression after Gene Therapy in a Mouse Model of Hemophilia B
18. A TFPI Inhibitory Half Life Extended Fusion Peptide Proves Efficacy in FVIII Knock out Mice and Marmoset Monkeys
19. Concomitant Administration Of Activated Prothrombin Complex Concentrate and Recombinant Activated Factor VII At Low Doses Are Efficacious and Safe In Hemophilic Mice
20. Preclinical Efficacy Testing of Baxter's Recombinant ADAMTS13 in a Mouse Model of TTP.
21. Impact of Factor IXa Content On Function, Safety and Efficacy of Recombinant Factor IX Products.
22. Peptides Inhibiting Tissue Factor Pathway Inhibitor Improve Hemostasis in Mice
23. Efficacy of Baxter’s Longer Acting rFVIII (BAX 855) in Mouse Models of Hemophilia A
24. Structural and Functional Characterization of Fucoidan and Its Procoagulant Effect in An Ex Vivo Model of Factor VIII-Inhibited Guinea Pigs
25. Pharmacokinetics of Baxter’s Longer Acting rFVIII (BAX 855) in Factor VIII Ko Mice, Rats and Cynomolgus Monkeys
26. Preclinical Efficacy Testing of Baxter's Recombinant FVIIa
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.